Last reviewed · How we verify
Oxymetazoline gel
Oxymetazoline gel is a Alpha-2 adrenergic agonist Small molecule drug developed by RDD Pharma Ltd. It is currently FDA-approved for Nasal congestion (topical gel), Facial erythema / rosacea (topical gel).
Oxymetazoline is a selective alpha-2 adrenergic receptor agonist that causes vasoconstriction of blood vessels in the nasal mucosa and skin.
Oxymetazoline is a selective alpha-2 adrenergic receptor agonist that causes vasoconstriction of blood vessels in the nasal mucosa and skin. Used for Nasal congestion (topical gel), Facial erythema / rosacea (topical gel).
At a glance
| Generic name | Oxymetazoline gel |
|---|---|
| Sponsor | RDD Pharma Ltd |
| Drug class | Alpha-2 adrenergic agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Otolaryngology |
| Phase | FDA-approved |
Mechanism of action
By binding to alpha-2 adrenergic receptors on vascular smooth muscle, oxymetazoline triggers vasoconstriction that reduces blood flow and swelling in affected tissues. In gel formulation, it is applied topically to reduce nasal congestion or facial erythema by shrinking engorged blood vessels. The vasoconstrictor effect is localized to the site of application, providing symptomatic relief without systemic absorption.
Approved indications
- Nasal congestion (topical gel)
- Facial erythema / rosacea (topical gel)
Common side effects
- Local irritation or burning at application site
- Rebound congestion with prolonged use
- Headache
- Nervousness or tremor (with systemic absorption)
Key clinical trials
- Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV (PHASE2)
- LEV102 Topical Gel in Acquired Blepharoptosis (PHASE1, PHASE2)
- A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers (PHASE1)
- Intra-anal Oxymetazoline in Healthy Adult Volunteers (PHASE1)
- Sphenopalatine Ganglion Block for Postdural Puncture Headache in the Emergency Department (NA)
- The Effect of Oxymetazoline Gel on Anal Pressure and Incontinence in Spinal Cord Injury Patients (PHASE1, PHASE2)
- A Study to Evaluate Topical Phenylephrine Gel in the Management of Faecal Incontinence (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxymetazoline gel CI brief — competitive landscape report
- Oxymetazoline gel updates RSS · CI watch RSS
- RDD Pharma Ltd portfolio CI
Frequently asked questions about Oxymetazoline gel
What is Oxymetazoline gel?
How does Oxymetazoline gel work?
What is Oxymetazoline gel used for?
Who makes Oxymetazoline gel?
What drug class is Oxymetazoline gel in?
What development phase is Oxymetazoline gel in?
What are the side effects of Oxymetazoline gel?
What does Oxymetazoline gel target?
Related
- Drug class: All Alpha-2 adrenergic agonist drugs
- Target: All drugs targeting Alpha-2 adrenergic receptor
- Manufacturer: RDD Pharma Ltd — full pipeline
- Therapeutic area: All drugs in Dermatology / Otolaryngology
- Indication: Drugs for Nasal congestion (topical gel)
- Indication: Drugs for Facial erythema / rosacea (topical gel)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing